Clinical trial
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell…
NCT00265928 · University of Virginia, Other · Terminated
Key facts
| NCT number | NCT00265928 |
|---|---|
| Title | Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
| Official title | VELCADE (Bortezomib) for Injection - Phase II Study of Bortezomib and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | bortezomib, rituximab, antibody therapy, biological therapy, enzyme inhibitor therapy, monoclonal antibody therapy |
| Enrollment | 46 |
| First posted | Dec 15, 2005 |
| Last update posted | Jan 28, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: